Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
Bioaffinity Technologies, Inc., a Delaware corporation, filed this Current Report on Form 8-K on May 15, 2024. The filing serves to disseminate a press release containing financial information for the quarter ended March 31, 2024. The company is designated as an emerging growth company and trades on The Nasdaq Stock Market LLC under the symbols BIAF (Common Stock) and BIAFW (Warrants).
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly references a press release (Exhibit 99.1) as the source for these figures but does not embed the data within the 8-K text itself.
Material Changes
No material changes versus prior periods are detailed in the text of this filing. The document functions solely as a notification of the issuance of the press release regarding the quarter ended March 31, 2024.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings. No specific guidance, management commentary, risks, or contingencies are described in the text provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 15, 2024) for actual financial results for the quarter ended March 31, 2024.
- Verify the company's status as an emerging growth company and its implications for financial reporting.
- Confirm trading status and warrant details for symbols BIAF and BIAFW on Nasdaq.
- Note that the financial data in the press release is not incorporated by reference into future SEC filings.